BIOCRYST PHARMACEUTICALS, INC. Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options (Deprecated 2017-01-31)
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options (Deprecated 2017-01-31) of $15.65 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions · last filed 2017-02-27
- BIOCRYST PHARMACEUTICALS, INC. employee service share-based compensation, tax benefit realized from exercise of stock options (deprecated 2017-01-31) for fiscal 2016 was $15.65M, a 0.00% change from fiscal 2015.
- BIOCRYST PHARMACEUTICALS, INC. employee service share-based compensation, tax benefit realized from exercise of stock options (deprecated 2017-01-31) for fiscal 2015 was $15.65M, a 98.42% increase from fiscal 2014.
- BIOCRYST PHARMACEUTICALS, INC. employee service share-based compensation, tax benefit realized from exercise of stock options (deprecated 2017-01-31) for fiscal 2014 was $7.89M, a 76.35% increase from fiscal 2013.
- BIOCRYST PHARMACEUTICALS, INC. employee service share-based compensation, tax benefit realized from exercise of stock options (deprecated 2017-01-31) for fiscal 2013 was $4.47M, a 8.71% decline from fiscal 2012.
| Period end | Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options (Deprecated 2017-01-31) 12 month |
|---|---|
| 2016-12-31 | $15.65M 10-K · filed 2017-02-27 |
| 2015-12-31 | $15.65M 10-K · filed 2016-02-26 |
| 2014-12-31 | $7.89M 10-K · filed 2015-03-02 |
| 2013-12-31 | $4.47M 10-K · filed 2014-03-10 |
| 2012-12-31 | $4.90M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |